Victory Capital Management
KIN

Victory Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Victory Capital Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,027
Closed -$24K – 3615
2020
Q1 		$24K Buy
+6,027
New +$51.2K ﹤0.01% 2781
2019
Q4 		– Sell
-6,532
Closed -$45K – 3589
2019
Q3 		$45K Buy
+6,532
New +$47.9K ﹤0.01% 2734

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Victory Capital Management's KIN Position: Q2 2020 in Review

Victory Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2020, closing a stake of 6,027 shares — an estimated $24K sold.

Victory Capital Management first reported a position in KIN in Q3 2019 and held it in 2 quarters. The position peaked at $45K in Q3 2019. 83 funds tracked by Wall St. Rank hold KIN as of Q2 2020.

  • Victory Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 6,027 Kindred Biosciences, Inc. shares in Q2 2020, an estimated $24K.
  • Victory Capital Management first reported a position in Kindred Biosciences, Inc. in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Kindred Biosciences, Inc. position peaked at $45K in Q3 2019.
  • 83 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.